This content is in French.
IBD: a double burden
19 mai 2025
#MetabolicSyndrome #IBD #CrohnsDisease #CorticosteroidTherapy
#UlcerativeColitis #ChronicInflammation
Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, are known for their impact not only on the digestive system but also systemically. Among the associated complications, metabolic syndrome (MetS) is emerging as an increasingly concerning issue. Patients with IBD face a higher metabolic risk, stemming from a complex interplay between chronic inflammation, immune dysregulation, and profound metabolic alterations.
Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, are known for their impact not only on the digestive system but also systemically. Among the associated complications, metabolic syndrome (MetS) is emerging as an increasingly concerning issue. Patients with IBD face a higher metabolic risk, stemming from a complex interplay between chronic inflammation, immune dysregulation, and profound metabolic alterations.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Janani, K. V., et al. (2025). Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale. Journal of health, population, and nutrition, 44(1), 112
View the source
